Indication
Multiple Sclerosis
The Multiple Sclerosis pipeline: 45 tracked drugs, 26 approved for this indication.
26 approved / phase 49 Phase 33 Phase 23 Phase 14 preclinical / unstaged
Compare the share prices of listed companies in Multiple Sclerosis →
Total attributable cost
$65.6B
$65,612/patient
Drug spend
$35.2B
$35,154/patient
54% of total cost is drugs
All US adult MS forms and disability strata (rounded prevalence context) · US